MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis

TSX:MBX • CA59501P1045

0.24 CAD
0 (0%)
Last: Feb 25, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall MBX gets a fundamental rating of 4 out of 10. We evaluated MBX against 22 industry peers in the Biotechnology industry. The financial health of MBX is average, but there are quite some concerns on its profitability. MBX has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • MBX had negative earnings in the past year.
  • In the past year MBX has reported a negative cash flow from operations.
  • In multiple years MBX reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: MBX reported negative operating cash flow in multiple years.
MBX.CA Yearly Net Income VS EBIT VS OCF VS FCFMBX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2M -2M 4M -4M -6M

1.2 Ratios

  • MBX's Return On Assets of -6.00% is amongst the best of the industry. MBX outperforms 86.36% of its industry peers.
  • MBX's Return On Equity of -8.08% is amongst the best of the industry. MBX outperforms 86.36% of its industry peers.
Industry RankSector Rank
ROA -6%
ROE -8.08%
ROIC N/A
ROA(3y)1.04%
ROA(5y)3.95%
ROE(3y)1.4%
ROE(5y)5.76%
ROIC(3y)N/A
ROIC(5y)N/A
MBX.CA Yearly ROA, ROE, ROICMBX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • MBX has a Gross Margin of 53.02%. This is amongst the best in the industry. MBX outperforms 81.82% of its industry peers.
  • MBX's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for MBX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.11%
GM growth 5Y3.66%
MBX.CA Yearly Profit, Operating, Gross MarginsMBX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • MBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MBX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for MBX has been increased compared to 5 years ago.
  • The debt/assets ratio for MBX is higher compared to a year ago.
MBX.CA Yearly Shares OutstandingMBX.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
MBX.CA Yearly Total Debt VS Total AssetsMBX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of 1.76, we must say that MBX is in the distress zone and has some risk of bankruptcy.
  • MBX has a Altman-Z score of 1.76. This is in the better half of the industry: MBX outperforms 77.27% of its industry peers.
  • A Debt/Equity ratio of 0.24 indicates that MBX is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.24, MBX perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Altman-Z 1.76
ROIC/WACCN/A
WACC7.58%
MBX.CA Yearly LT Debt VS Equity VS FCFMBX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M

2.3 Liquidity

  • A Current Ratio of 8.48 indicates that MBX has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 8.48, MBX belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
  • MBX has a Quick Ratio of 5.17. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of MBX (5.17) is better than 86.36% of its industry peers.
Industry RankSector Rank
Current Ratio 8.48
Quick Ratio 5.17
MBX.CA Yearly Current Assets VS Current LiabilitesMBX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The earnings per share for MBX have decreased strongly by -163.28% in the last year.
  • Looking at the last year, MBX shows a very negative growth in Revenue. The Revenue has decreased by -26.81% in the last year.
  • Measured over the past years, MBX shows a quite strong growth in Revenue. The Revenue has been growing by 12.05% on average per year.
EPS 1Y (TTM)-163.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-440.62%
Revenue 1Y (TTM)-26.81%
Revenue growth 3Y-0.87%
Revenue growth 5Y12.05%
Sales Q2Q%-40.51%

3.2 Future

  • MBX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.75% yearly.
  • MBX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.96% yearly.
EPS Next Y33.33%
EPS Next 2Y52.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year35.93%
Revenue Next 2Y29.96%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MBX.CA Yearly Revenue VS EstimatesMBX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
MBX.CA Yearly EPS VS EstimatesMBX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.02 -0.02 0.04 0.06

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MBX. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 5.94, which indicates a rather cheap valuation of MBX.
  • Based on the Price/Forward Earnings ratio, MBX is valued cheaper than 95.45% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of MBX to the average of the S&P500 Index (28.13), we can say MBX is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 5.94
MBX.CA Price Earnings VS Forward Price EarningsMBX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MBX indicates a rather cheap valuation: MBX is cheaper than 95.45% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 145.76
MBX.CA Per share dataMBX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15 0.2

4.3 Compensation for Growth

  • MBX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • MBX's earnings are expected to grow with 52.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.75%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • MBX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MICROBIX BIOSYSTEMS INC

TSX:MBX (2/25/2026, 7:00:00 PM)

0.24

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-13
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners14.76%
Ins Owner ChangeN/A
Market Cap33.25M
Revenue(TTM)18.59M
Net Income(TTM)-2.25M
Analysts80
Price Target0.51 (112.5%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-44.44%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.94
P/S 1.79
P/FCF N/A
P/OCF N/A
P/B 1.2
P/tB 1.38
EV/EBITDA 145.76
EPS(TTM)-0.02
EYN/A
EPS(NY)0.04
Fwd EY16.83%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0.13
BVpS0.2
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -6%
ROE -8.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.02%
FCFM N/A
ROA(3y)1.04%
ROA(5y)3.95%
ROE(3y)1.4%
ROE(5y)5.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.11%
GM growth 5Y3.66%
F-Score2
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Debt/EBITDA 34.25
Cap/Depr 44.81%
Cap/Sales 4.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.48
Quick Ratio 5.17
Altman-Z 1.76
F-Score2
WACC7.58%
ROIC/WACCN/A
Cap/Depr(3y)83.66%
Cap/Depr(5y)119.48%
Cap/Sales(3y)5.99%
Cap/Sales(5y)7.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-163.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-440.62%
EPS Next Y33.33%
EPS Next 2Y52.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-26.81%
Revenue growth 3Y-0.87%
Revenue growth 5Y12.05%
Sales Q2Q%-40.51%
Revenue Next Year35.93%
Revenue Next 2Y29.96%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-139.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.01%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-135.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.85%
OCF growth 3YN/A
OCF growth 5YN/A

MICROBIX BIOSYSTEMS INC / MBX.CA FAQ

What is the ChartMill fundamental rating of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MBX.CA.


What is the valuation status of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?

ChartMill assigns a valuation rating of 5 / 10 to MICROBIX BIOSYSTEMS INC (MBX.CA). This can be considered as Fairly Valued.


What is the profitability of MBX stock?

MICROBIX BIOSYSTEMS INC (MBX.CA) has a profitability rating of 3 / 10.